Skip to main content
. 2019 Jan 10;9:1902. doi: 10.3389/fphys.2018.01902

Table 3.

Summary ORs and 95% CI of vitamin D receptor gene polymorphisms and polycystic ovary syndrome risk.

Locus N* OR 95% CI P I2 OR 95% CI P I2 OR 95% CI P I2 OR 95% CI P I2 OR 95% CI P I2
Fok I C/T (rs10735810) T vs. C CT vs. CC TT vs. CC CT+TT vs. CC TT vs. CC+CT
Total 7 1.04 0.83–1.30 0.77 53.2 1.08 0.89–1.32 0.42 7.0 0.89 0.64–1.25 0.50 35.6 1.06 0.88–1.27 0.56 36.4 0.86 0.63–1.18 0.34 23.6
ETHNICITY
Caucasian 5 1.14 0.80–1.60 0.47 66.6 1.18 0.92–1.53 0.20 19.3 1.07 0.52–2.19 0.86 54.1 1.22 0.84–1.77 0.31 49.5 0.96 0.53–1.76 0.91 45.0
Asian 2 0.91 0.72–1.16 0.46 0 0.95 0.70–1.30 0.77 0 0.77 0.41–1.43 0.40 0 0.92 0.69–1.24 0.60 0 0.79 0.43–1.45 0.44 0
DESIGN
Hospital-B 3 1.04 0.86–1.27 0.65 28.1 1.04 0.80–1.36 0.75 0.0 1.07 0.70–1.56 0.76 0 1.05 0.82–1.36 0.68 15.9 1.06 0.71–1.59 0.78 0
Healthy-B 4 1.08 .0.69–1.69 0.72 68.7 1.14 0.85–1.52 0.39 33.8 0.78 0.33–1.83 0.56 45.1 1.19 0.72–1.97 0.50 57.5 0.62 0.37–1.03 0.07 23.7
GENOTYPING
PCR-RFLP 5 1.17 0.89–1.54 0.26 45.9 1.15 0.91–1.46 0.27 26.6 1.14 0.70–1.84 0.59 11.6 1.22 0.88–1.68 0.24 42.3 1.09 0.68–1.75 0.72 0
Other 2 0.82 0.56–1.19 0.30 57.7 0.95 0.67–1.35 0.76 0 0.62 0.25–1.53 0.30 66.6 0.88 0.63–1.23 0.47 0 0.65 0.29–1.44 0.28 66.5
BsmI A/G (rs1544410) G vs. A AG vs. AA GG vs. AA AG+GG vs. AA GG vs. AA+AG
Total 7 1.17 0.95–1.45 0.14 49.6 1.15 0.75–1.78 0.52 59.9 1.28 0.95–1.74 0.11 35.7 1.22 0.82–1.81 0.34 57.1 1.16 0.93–1.45 0.18 19.8
HWE-yes 5 1.17 0.90–1.51 0.24 45.2 1.10 0.67–1.82 0.70 50.8 1.38 0.96–2.00 0.09 36.9 1.19 0.76–1.89 0.48 47.5 1.26 0.84–1.89 0.27 42.2
HWE-no 2 1.20 0.70–2.07 0.50 78.2 1.27 0.40–4.01 0.68 84.7 1.15 0.48–2.72 0.76 61.2 1.26 0.43–3.64 0.67 84.1 1.06 0.72–1.58 0.16 0
ETHNICITY
Caucasian 5 1.02 0.86–1.21 0.84 0.0 0.90 0.64–1.26 0.54 31.4 0.99 0.68–1.44 0.95 0.0 0.94 0.68–1.30 0.72 11.7 1.08 0.84–1.39 0.57 27.2
Asian 2 1.62 1.24–2.11 < 0.01 0.0 2.08 1.26–3.20 < 0.01 0 2.21 1.29–3.77 < 0.01 0.0 2.12 1.42–3.16 < 0.01 0 1.51 0.95–2.39 0.08 0
DESIGN
Hospital-B 4 1.26 0.97–1.64 0.08 60.1 1.35 0.81–2.24 0.25 64.5 1.43 0.87–2.35 0.16 51.3 1.41 0.86–2.29 0.17 65.5 1.22 0.95–1.57 0.12 0
Healthy-B 3 0.96 0.71–1.31 0.82 20.8 0.82 0.33–2.00 0.66 59.8 0.90 0.45–1.78 0.76 0 0.90 0.45–1.80 0.76 40.0 1.28 0.49–3.30 0.62 58.9
GENOTYPING
PCR-RFLP 5 1.29 0.99–1.99 0.06 46.3 1.17 0.62–2.20 0.63 71.6 1.49 0.85–2.60 0.16 40.7 1.29 0.74–2.25 0.37 66.9 1.30 0.97–1.80 0.07 0
Other 2 0.98 0.68–1.41 0.89 55.3 1.04 0.65–1.65 0.87 0 1.04 0.65–1.69 0.86 28.1 1.04 0.67–1.61 0.85 0 0.94 0.53–1.66 0.84 62.2
ApaI A/C (rs7975232) C vs. A AC vs. AA CC vs. AA AC+CC vs. AA CC vs. AA+AC
Total 8 1.20 1.06–1.35 < 0.01 29.7 1.10 0.80–1.49 0.56 59.7 1.49 1.17–1.91 < 0.01 0 1.21 0.94–1.57 0.15 51.3 1.36 1.09–1.69 0.01 12.8
HWE-yes 5 1.22 1.03–1.45 0.02 32.6 1.00 0.58–1.72 0.99 72.6 1.61 1.13–2.27 0.01 0 1.14 0.70–1.83 0.60 68.8 1.55 1.15–2.10 < 0.01 0
HWE-no 3 1.21 0.95–1.54 0.13 49.0 1.21 0.94–1.56 0.14 0 1.38 0.97–1.97 0.07 18.1 1.26 1.00–1.59 0.06 0 1.25 0.71–2.20 0.44 62.7
ETHNICITY
Caucasian 5 1.11 0.95–1.30 0.18 0 0.98 0.60–1.62 0.95 72.6 1.28 0.94–1.74 0.12 0 1.07 0.74–1.57 0.71 58.0 1.20 0.91–1.57 0.20 0
Asian 3 1.41 1.02–1.95 0.04 63.9 1.19 0.90–1.57 0.23 18.9 1.97 1.30–2.97 < 0.01 22.8 1.42 0.96–2.10 0.08 48.6 1.72 1.19–2.50 < 0.01 0
DESIGN
Hospital-B 4 1.31 1.02–1.67 0.03 55.8 1.16 0.71–1.89 0.56 68.9 1.59 1.17–2.15 < 0.01 38.1 1.33 0.90–1.97 0.16 61.1 1.50 0.98–2.30 0.06 59.9
Healthy-B 4 1.11 0.93–1.34 0.24 0 1.03 0.64–1.64 0.91 60.5 1.31 0.85–2.02 0.22 0 1.10 0.74–1.62 0.64 49.9 1.26 0.85–1.87 0.25 0
GENOTYPING
PCR-RFLP 5 1.22 1.00–1.49 0.05 45.4 0.95 0.66–1.36 0.78 58.5 1.60 1.18–2.16 < 0.01 3.8 1.10 0.80–1.54 0.52 57.8 1.63 1.24–2.15 < 0.01 0
Other 2 1.17 0.94–1.46 0.16 0 1.61 1.12–2.32 0.01 0 1.30 0.85–2.00 0.22 0 1.50 1.07–2.10 0.02 0 0.98 0.68–1.41 0.89 0
TaqI T/C (rs731236) C vs. T TC vs. TT CC vs. TT TC+ CC vs. TT CC vs. TT+ TC
Total 9 1.16 0.94–1.44 0.18 66.5 1.00 0.75–1.34 0.99 58.5 1.44 0.97–2.15 0.07 54.2 1.10 0.82–1.48 0.52 65.4 1.37 1.09–1.74 0.01 38.3
HWE-yes 7 1.16 0.93–1.46 0.19 61.3 1.07 0.79–1.45 0.66 51.2 1.39 0.87–2.22 0.17 57.8 1.15 0.85–1.56 0.38 58.1 1.31 0.90–1.90 0.16 43.4
HWE-no 2 1.15 0.52–2.53 0.73 88.0 0.81 0.32–2.05 0.65 81.1 1.65 0.65–4.18 0.29 56.3 0.95 0.33–2.80 0.93 87.9 1.91 1.09–3.33 0.02 0
ETHNICITY
Caucasian 6 1.20 0.89–1.60 0.23 67.2 1.13 0.79–1.63 0.50 54.2 1.46 0.79–2.71 0.23 64.8 1.20 0.82–1.76 0.34 62.8 1.33 0.81–2.17 0.26 52.5
Asian 3 1.11 0.74–1.67 0.60 76.4 0.82 0.51–1.32 0.41 63.0 1.45 0.99–2.12 0.06 36.9 0.95 0.55–1.65 0.86 75.9 1.55 1.08–2.22 0.02 0
DESIGN
Hospital-B 4 1.03 0.74–1.44 0.85 74.5 0.83 0.59–1.17 0.29 48.0 1.23 0.66–2.27 0.52 63.5 0.91 0.60–1.38 0.66 68.0 1.33 0.79–2.22 0.28 54.0
Healthy-B 5 1.31 1.00–1.70 0.05 48.0 1.21 0.78–1.87 0.40 57.9 1.70 0.98–2.96 0.06 46.0 1.33 0.89–1.98 0.16 56.4 1.51 1.09–2.08 0.01 30.8
GENOTYPING
PCR-RFLP 7 1.25 0.97–1.60 0.08 64.5 0.98 0.69–1.40 0.91 61.8 1.74 1.30–2.33 < 0.01 27.3 1.14 0.79–1.63 0.50 68.5 1.68 1.28–2.22 < 0.01 0
Other 2 0.89 0.71–1.13 0.34 38.9 1.09 0.55–2.17 0.81 71.8 0.73 0.44–1.19 0.20 0 1.01 0.55–1.86 0.98 68.1 0.75 0.48–1.18 0.22 0
*

Numbers of comparisons.

Hospital-B, Hospital-based control; Healthy-B, Healthy-based control; RT-PCR, Real-time PCR.